The effect of PDB on subsequent all-cause mortality within 2 years was estimated by time-adjusted Cox proportional hazards regression.
BACKGROUND The PE Plus Post-Approval Study (PE Plus PAS) was designed to examine long-term outcomes among patients treated with advanced generation, everolimus-eluting, platinum chromium PROMUS Element stents (Boston Scientific, Marlborough, MA) in unselected patients treated in routine practice. This is the first report of 2-year results from this large multicenter post-approval study.
METHODS PE Plus PAS was a prospective, open-label, multicenter observational study enrolling 2684 patients at 52 sites in the US. Follow-up was at 30 days, 6 months, and 1 year, and will continue annually through 5 years. The primary endpoint was 12-month cardiac death or myocardial infarction (CD/MI) in 'PLATINUM-like' patients who received PROMUS Element Plus in PE Plus PAS, PE PROVE and patients from the PLATINUM Workhorse/Small Vessel trials compared to a performance goal (3.2%) derived from outcomes in SPIRIT IV and the PLATINUM trial. The PLATINUM-like patient cohort was defined as all patients that met the criteria for enrollment in the PLATINUM trial. A Clinical Events Committee adjudicated major adverse cardiac events and their relatedness to the study stent.
RESULTS
In the PE Plus PAS, 30% of patients were female, mean age was 64 years, 37% had medically treated diabetes, and more than three-quarters were treated for hyperlipidemia and hypertension. At baseline, mean lesion length was 17AE10 mm and mean reference vessel diameter was 2.9AE0.5 mm (in 3595 treated lesions). PLATINUM-like patients accounted for 29% of the overall PE Plus PAS patient population. For the primary endpoint, 12-month CD/MI in PLATINUM-like patients was 1.8% (33/1855) with a upper 1-sided 95% confidence interval of 2.3%, which was significantly less than the prespecified performance goal of 3.2% (Pnoninferiority<0.001).
In the overall PE Plus population, 12-month major adverse cardiac events were low.
CONCLUSIONS The 2-year results from the PE Plus PAS will be available for presentation for the first time at TCT 2015 and will show favorable performance and safety for the PROMUS Element Plus everolimus-eluting stent at 2 years in an unselected patient population. RESULTS During a median of 4.6-year of follow-up, the cumulative incidence of all-cause death was not significantly different between the successful and unsuccessful CTO-PCI (8.0% vs. 7.1%, P ¼ 0.83). The cumulative rate of target vessel revascularization (TVR) and coronary artery bypass grafting (CABG) was remarkably less in patients with successful PCI compared with those with unsuccessful PCI (TVR; 4.4% vs. 20.9%, P < 0.001, CABG; 0.4% vs. 16.7%, P < 0.001). The adjusted risks of all-cause death (hazard ratio [HR] 1.19, 95% confidence interval [CI] 0.59 -2.43, P ¼ 0.62) and the composite of death or myocardial infarction ([MI], HR 1.06, 95% CI 0.56 -2.03, P ¼ 0.96) remained comparable between groups, whereas the adjusted risk of TVR and CABG was significantly higher in patients with unsuccessful CTO PCI. Among 879 subjects who eventually had a complete revascularization state for the non-CTO vessels, the risks of death or the composite of death or MI were not different between patients who further underwent successful recanalization of the remaining CTO and those who did not. This finding was consistent regardless of whether the patient had a multi-vessel disease including CTO or only had a single CTO.
CONCLUSIONS Successful CTO-PCI compared with unsuccessful PCI was not associated with lesser risk for 4.6-year mortality, but was associated with significantly less subsequent CABG. 
